Fulcrum Therapeutics Inc (NASDAQ: FULC) on Friday, soared 9.43% from the previous trading day, before settling in for the closing price of $2.97. Within the past 52 weeks, FULC’s price has moved between $2.86 and $13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.10% annually for the last half of the decade. The company achieved an average annual earnings per share of 90.17%. With a float of $46.61 million, this company’s outstanding shares have now reached $61.92 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.44%, operating margin of -37.66%, and the pretax margin is -22.15%.
Fulcrum Therapeutics Inc (FULC) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fulcrum Therapeutics Inc is 13.58%, while institutional ownership is 87.58%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.4 earnings per share (EPS) for the period topping the consensus outlook (set at -0.43) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Fulcrum Therapeutics Inc (FULC) is currently performing well based on its current performance indicators. A quick ratio of 18.44 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.04 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.03 million. That was better than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.44%. Additionally, its Average True Range was 0.24.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 5.36%, which indicates a significant decrease from 36.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.72% in the past 14 days, which was lower than the 167.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.41, while its 200-day Moving Average is $7.14. However, in the short run, Fulcrum Therapeutics Inc’s stock first resistance to watch stands at $3.38. Second resistance stands at $3.52. The third major resistance level sits at $3.73. If the price goes on to break the first support level at $3.03, it is likely to go to the next support level at $2.82. Assuming the price breaks the second support level, the third support level stands at $2.68.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
Market capitalization of the company is 191.83 million based on 53,939K outstanding shares. Right now, sales total 2,810 K and income totals -97,340 K. The company made 80,000 K in profit during its latest quarter, and 55,410 K in sales during its previous quarter.
